Outcomes after early treatment with hydroxychloroquine and azithromycin : An analysis of a database of 30,423 COVID-19 patients
© 2023 The Authors. Published by Elsevier Ltd..
Background: Many studies have evaluated the use of hydroxychloroquine in COVID-19. Most retrospective observational studies demonstrate a benefit of using HCQ on mortality, but not most randomized clinical trials.
Methods: We analyzed raw data collected from a cohort of 30,423 patients with COVID-19 cared for at IHU Méditerranée Infection in Marseille France and extracted from the DRYAD open data platform. We performed univariate and multivariable logistic regressions with all-cause mortality within six weeks. Multivariable logistic regressions were adjusted for sex, age group (<50, 50-69, 70-89 and > 89 years), periods (or variants), and type of patient management.
Results: Among 30,202 patients for whom information on treatment was available, 191/23,172 (0.82%) patients treated with HCQ-AZ died, compared to 344/7030 (4.89%) who did not receive treatment with HCQ-AZ. HCQ-AZ therapy was associated with a lower mortality than treatment without HCQ-AZ (odds ratio (OR) 0.16; 95% confidence interval (CI), 0.14-0.19). After adjustment for sex, age, period, and patient management, HCQ-AZ was associated with a significantly lower mortality rate (adjusted OR (aOR) 0.55, 95% CI 0.45-0.68). On a subsample of 21,664 patients with available variant information, results remained robust after adjustment on sex, age, patient management and variant (aOR 0.55; 95% CI 0.44-0.69). On a subsample of 16,063 patients, HCQ-AZ was still associated with a significantly lower mortality rate (aOR 0.47, 95%CI 0.29-0.75) after adjustment for sex, age, period, patient management, vaccination status and comorbidities.
Conclusion: Analysis of this large online database showed that HCQ-AZ was consistently associated with the lowest mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
New microbes and new infections - 55(2023) vom: 21. Okt., Seite 101188 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brouqui, Philippe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Azithromycin |
|---|
| Anmerkungen: |
Date Revised 01.12.2023 published: Electronic-eCollection Dryad: 10.5061/dryad.ksn02v78v Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.nmni.2023.101188 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365154768 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365154768 | ||
| 003 | DE-627 | ||
| 005 | 20231226101053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nmni.2023.101188 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365154768 | ||
| 035 | |a (NLM)38024333 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brouqui, Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes after early treatment with hydroxychloroquine and azithromycin |b An analysis of a database of 30,423 COVID-19 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Dryad: 10.5061/dryad.ksn02v78v | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Published by Elsevier Ltd. | ||
| 520 | |a Background: Many studies have evaluated the use of hydroxychloroquine in COVID-19. Most retrospective observational studies demonstrate a benefit of using HCQ on mortality, but not most randomized clinical trials | ||
| 520 | |a Methods: We analyzed raw data collected from a cohort of 30,423 patients with COVID-19 cared for at IHU Méditerranée Infection in Marseille France and extracted from the DRYAD open data platform. We performed univariate and multivariable logistic regressions with all-cause mortality within six weeks. Multivariable logistic regressions were adjusted for sex, age group (<50, 50-69, 70-89 and > 89 years), periods (or variants), and type of patient management | ||
| 520 | |a Results: Among 30,202 patients for whom information on treatment was available, 191/23,172 (0.82%) patients treated with HCQ-AZ died, compared to 344/7030 (4.89%) who did not receive treatment with HCQ-AZ. HCQ-AZ therapy was associated with a lower mortality than treatment without HCQ-AZ (odds ratio (OR) 0.16; 95% confidence interval (CI), 0.14-0.19). After adjustment for sex, age, period, and patient management, HCQ-AZ was associated with a significantly lower mortality rate (adjusted OR (aOR) 0.55, 95% CI 0.45-0.68). On a subsample of 21,664 patients with available variant information, results remained robust after adjustment on sex, age, patient management and variant (aOR 0.55; 95% CI 0.44-0.69). On a subsample of 16,063 patients, HCQ-AZ was still associated with a significantly lower mortality rate (aOR 0.47, 95%CI 0.29-0.75) after adjustment for sex, age, period, patient management, vaccination status and comorbidities | ||
| 520 | |a Conclusion: Analysis of this large online database showed that HCQ-AZ was consistently associated with the lowest mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Azithromycin | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Open data | |
| 650 | 4 | |a Real-world evidence | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Million, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Parola, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Mccullough, Peter A |e verfasserin |4 aut | |
| 700 | 1 | |a Raoult, Didier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t New microbes and new infections |d 2013 |g 55(2023) vom: 21. Okt., Seite 101188 |w (DE-627)NLM243163762 |x 2052-2975 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g day:21 |g month:10 |g pages:101188 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nmni.2023.101188 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |b 21 |c 10 |h 101188 | ||